GAP- Global Alzheimer’s Platform Foundation Webinar

Aducanumab Data Review

Samantha Budd Haeberlein, PhD
Senior Vice President, Head Neurodegeneration Development Unit Biogen

February 23, 2021
This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to results from the Phase 3 clinical studies of aducanumab; the potential clinical effects of aducanumab; the potential benefits, safety, and efficacy of aducanumab; potential regulatory discussions, submissions, and approvals and the timing thereof; clinical development programs, clinical trials, data readouts, and presentations related to aducanumab; the treatment of Alzheimer’s disease; the potential of Biogen’s pipeline programs, including aducanumab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later-stage or larger-scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including actual timing and content of submissions to and decisions made by the regulatory authorities regarding aducanumab; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen’s drug candidates, including aducanumab; the occurrence of adverse safety events and/or unexpected concerns that may arise from additional data or analysis; risks of unexpected costs or delays; the risks of other unexpected hurdles; uncertainty of success in the development and potential commercialization of aducanumab; failure to protect and enforce Biogen’s data, intellectual property, and other proprietary rights and uncertainties relating to intellectual property claims and challenges; risks relating to the potential launch of aducanumab, including preparedness of healthcare providers to treat patients, the ability to obtain and maintain adequate reimbursement for aducanumab, and other unexpected difficulties or hurdles; product liability claims; third-party collaboration risks; and the other risks and uncertainties that are described in the Risk Factors section of Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. The statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this presentation. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Aducanumab is an investigational drug that is currently under regulatory review. It is not approved for use in any country at this time.
Thank You to Everyone Who Has Contributed to Alzheimer’s Disease Research!

Aducanumab Phase 3 trials included 3285 patients at 348 sites in 20 countries

Countries with active sites included:
Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, the Netherlands, Poland, Portugal, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Biogen Position on the FDA Advisory Committee

Biogen stands behind the analyses and results of aducanumab:

- The core joint briefing book (FDA & Biogen) is the first ever in the neurology division
- The totality of data provides substantial evidence of clinical effectiveness of aducanumab, as demonstrated by study 302 (EMERGE) and supported by study 103 (PRIME)
- Biogen and the FDA concluded that partially discordant results of study 301 (ENGAGE) do not meaningfully detract from the persuasiveness of study 302
- We have applied the highest scientific rigor and integrity in the analyses submitted
- We recognize the complexity of the dataset and the challenges associated with the first positive Ph3 study in Alzheimer
Alzheimer’s Disease Presents a Significant Unmet Medical Need

- As of 2018, there were about 50 million people living with dementia worldwide\(^a\)
- Progressive neurological disorder resulting in memory loss, behavioral symptoms, and loss of ability to perform daily activities
- In advanced stages of dementia patients become completely dependent
- Alzheimer’s disease is ultimately fatal
- No available treatment that alters the course of disease

\(^a\) 2018 Alzheimer’s Disease International
The Two Pathological Hallmarks of Alzheimer’s Disease in the Brain Are Aβ Plaques and Neurofibrillar Tangles

1) Amyloid beta peptides are released extraneuronally as monomers

2) Aggregation of Aβ

3) Intraneuronal tau phosphorylation and aggregation

4) Synaptic dysfunction, inflammation and neuronal death

Aβ=amyloid beta; APP=amyloid precursor protein.
Aducanumab: Targeting Alzheimer’s Disease Pathology

Aducanumab Treatment: Reduced Progression of Alzheimer’s Disease

Amyloid β Aggregation
Monomers
Oligomer
Fibrils
Amyloid β Plaque
Healthy Neuron
Amyloid Plaque Reduction
Dysfunctional and Dying Neurons
Dysfunctional Microglia
No treatment
Aducanumab Is Differentiated From the First Generation of Anti-Aβ Antibodies

Molecular Characteristics of Aducanumab

- Specificity for neurotoxic aggregated forms of Aβ
- Effector-function enabling immune cell-mediated clearance of aggregated Aβ

Key Clinical Trial Design Elements

- Inclusion of patients with biomarker-confirmed early symptomatic Alzheimer’s disease
- Demonstration of robust reduction in pathology
- Appropriate clinical outcome measures

- Aducanumab was the first of this generation of antibodies to demonstrate proof of concept before initiating phase 3 trials
- Aducanumab is the only program at this time to have read out with positive results in phase 3 trials*

*Primary and secondary endpoints were met in Study 302. In Study 301, patients—with the opportunity for full 10mg/kg dosing had results similar to Study 302.
Aducanumab Clinical Development Program

- **Phase 1**: Study 101, n=53 (Single ascending dose)
- **Phase 1b/2**: Study 103, n=197 (Proof-of-Concept), Study 103 Long-term extension (LTE), Study 104, n=21 (Japanese phase 1), Study 102 (Bioavailability, n=28)
- **Phase 3/3b**: Study 301, n=1653, Study 301 Long-term extension (LTE), Study 302, n=1643, Study 302 Long-term extension (LTE), Study 304, n=max 2400
Phase 1b Study 103
Aducanumab Was the First Program Where Proof-of-Concept Was Demonstrated Prior to Phase 3

Change in CDR-SB

Baseline

One year

Placebo

3 mg/kg

6 mg/kg

10 mg/kg

Adjusted mean change from baseline at Week 54 (SE)

Placebo 1 mg/kg 3 mg/kg 6 mg/kg Titration 10 mg/kg

Change in CDR-SB

0.0 0.5 1.0 1.5 2.0 2.5

*p<0.05, compared with placebo (nominal)
Phase 3 Studies
# Aducanumab Phase 3 Trial Design
## Studies 301 and 302

<table>
<thead>
<tr>
<th>Studies</th>
<th>Two 18-month, randomized, double-blind, placebo-controlled, Phase 3 studies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Geography/ Sample size</strong></td>
<td>3285 patients at 348 sites in 20 countries</td>
</tr>
</tbody>
</table>
| **Population**   | • Early Alzheimer’s disease (MCI due to Alzheimer’s disease + mild Alzheimer’s disease dementia)  
  - MMSE 24-30, CDR-G 0.5, RBANS ≤ 85, with confirmed amyloid pathology |
| **Doses**        | • Two dosing regimens (low and high) and placebo; randomized 1:1:1            |
| **Primary endpoint** | • CDR-SB at 18 months                                                        |
| **Other endpoints** | • Secondary: MMSE, ADAS-Cog 13, ADCS-ADL-MCI  
  • Sub-studies: amyloid PET, tau PET, CSF disease-related biomarkers |

**Countries with active sites included:**  
Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, the Netherlands, Poland, Portugal, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Phase 3 Target Dose: 10 mg/kg With 6-Month Titration
Studies 301 and 302

24-week titration to reduce incidence of ARIA
14 doses of 10 mg/kg as in Study 103
Dose Regimen
Studies 301 and 302

Early enrolled patients in the high-dose arm received a lower dose

- ApoE ε4+ Low dose:
  - 3 mg/kg
  - 1 mg/kg
- ApoE ε4- Low dose:
  - 6 mg/kg
  - 3 mg/kg
  - 1 mg/kg
- ApoE ε4+ and ApoE ε4- High dose:
  - 10 mg/kg
  - 6 mg/kg
  - 3 mg/kg
  - 1 mg/kg

Expected # of 10 mg/kg in high-dose group:
- by Week 26: 1 dose
- by Week 50: 7 doses
- by Week 78: 14 doses

Median cumulative dose at Week 78:
- 56 mg/kg
- 98 mg/kg
- 153 mg/kg (post-PV4)
- 116 mg/kg (pre-PV4)

Phase 3 Studies Were Prematurely Terminated Following What Was Later Determined To be An Inaccurate Futility Prediction

- **Conditional power**: probability that primary efficacy endpoint analysis would be statistically significant at final analysis

- **Two key assumptions did not hold, and futility analysis did not accurately predict the future results**
  - Assumption 1: Identically designed studies would lead to similar study results. Therefore, pooled conditional power is appropriate
  - Assumption 2: Treatment effect will remain consistent over time

- At the time of futility analysis, Study 302 was trending positive, whereas Study 301 was not
Clinical Endpoints Measure Distinct, Important Symptoms of Cognition, Function, and Behavior

Five clinical rating scales were used in Studies 301 and 302

- Validated and widely used in early Alzheimer’s disease
- Covers the full scope of symptoms experienced by patients with Alzheimer’s disease
- Include a range of paradigms:
  - Expert clinical judgements based on patient examination and caregiver input
  - Patient and caregiver reports
  - Cognitive performance tests
- Together they cover a range of important and distinct dimensions with minimal overlap

Overlap of scales is only 5% to 25%
Study 302: High Dose Aducanumab Met Primary Objective of CDR-SB at Week 78

- Low dose: -15% (-0.569, 0.041) p=0.0901
- High dose: -22% (-0.694, -0.086) p=0.0120

n=numbers of randomized and dosed participants included in the analysis
Study 302: All Items Measured in Primary Endpoint (CDR-SB) Were Improved by High-Dose Aducanumab

Adjusted mean change from baseline at week 78

<table>
<thead>
<tr>
<th>Category</th>
<th>Placebo</th>
<th>High-dose aducanumab</th>
<th>Treatment difference (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orientation</td>
<td>0.26</td>
<td>0.34</td>
<td>-0.08 (−24%)</td>
</tr>
<tr>
<td>Community affairs</td>
<td>0.24</td>
<td>0.31</td>
<td>-0.07 (−23%)</td>
</tr>
<tr>
<td>Home and hobbies</td>
<td>0.23</td>
<td>0.29</td>
<td>-0.07 (−24%)</td>
</tr>
<tr>
<td>Judgment and problem solving</td>
<td>0.21</td>
<td>0.28</td>
<td>-0.07 (−25%)</td>
</tr>
<tr>
<td>Memory</td>
<td>0.17</td>
<td>0.25</td>
<td>-0.07 (−28%)</td>
</tr>
<tr>
<td>Personal care</td>
<td>0.17</td>
<td>0.20</td>
<td>-0.03 (−15%)</td>
</tr>
</tbody>
</table>
Study 302: High-dose Aducanumab Met All Clinical Endpoints Assessing Cognition and Function at Week 78

<table>
<thead>
<tr>
<th>Primary Endpoint</th>
<th>Secondary Endpoints</th>
<th>n=numbers of randomized and dosed participants included in the analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDR-SB</td>
<td>MMSE</td>
<td>ADAS-Cog13</td>
</tr>
<tr>
<td>% Difference vs placebo (95% CI)</td>
<td>p value</td>
<td>% Difference from placebo (95% CI)</td>
</tr>
<tr>
<td>Low-dose aducanumab</td>
<td>-15% (-0.569, 0.041)</td>
<td>3%</td>
</tr>
<tr>
<td>High-dose aducanumab</td>
<td>-22% (-0.694, -0.086)</td>
<td></td>
</tr>
<tr>
<td>Low-dose n=543</td>
<td>High-dose n=547</td>
<td>Low-dose n=543</td>
</tr>
<tr>
<td></td>
<td>p=0.0901</td>
<td></td>
</tr>
</tbody>
</table>
Study 302: Treatment Effect Observed in Exploratory Clinical Endpoint of NPI-10 Assessing Behavior at Week 78

Caregivers of patients who received high-dose aducanumab reported 84% less burden compared with caregivers of patients who received placebo.

Neuropsychiatric Inventory 10 (NPI-10)

-33% difference vs placebo
-0.5 (-1.62, 0.64)
p=0.3921

-87% difference vs placebo
-1.3 (-2.45, -0.20)
p=0.0215

Low-dose n=543
High-dose n=547

n=numbers of randomized and dosed participants included in the analysis
Study 302: Amyloid PET Shows Aducanumab Dose-Dependent Reduction in β-Amyloid Pathology

### Adjusted mean change from baseline (±SE)

<table>
<thead>
<tr>
<th>Analysis visit, week</th>
<th>Placebo</th>
<th>Low-dose aducanumab</th>
<th>High-dose aducanumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>159</td>
<td>159</td>
<td>170</td>
</tr>
<tr>
<td>26</td>
<td>129</td>
<td>129</td>
<td>138</td>
</tr>
<tr>
<td>78</td>
<td>93</td>
<td>100</td>
<td>109</td>
</tr>
</tbody>
</table>

**Diff. from placebo, Week 78**

- Placebo: 
  - 0.179
- Low-dose aducanumab: 
  - 0.278

**p<0.001 (nominal)**
Study 302: Aducanumab Reduced Biomarkers of Alzheimer’s Disease-specific Tau Pathophysiology and Neurodegeneration

**CSF p-Tau**

- Placebo: n=28
- Low dose: n=33
- High dose: n=17

Adjusted mean change from baseline (SE):

- Placebo: -20 SE
- Low dose: -15 SE
- High dose: -10 SE

**CSF t-Tau**

- Placebo: n=28
- Low dose: n=33
- High dose: n=17

Adjusted mean change from baseline (SE):

- Placebo: -20 SE
- Low dose: -15 SE
- High dose: -10 SE

*p<0.05, ** p<0.01 , *** p<0.001 (nominal)
n=numbers of randomized and dosed participants included in the analysis
Aducanumab Reduced Biomarkers of Tau Neurofibrillary Tangles in the Brain
Pooled Data, Studies 301 and 302

* p<0.05, *** p<0.001 (nominal).

n=numbers of randomized and dosed participants included in the analysis
Study 302: Aducanumab-related Biomarker Changes Are Associated With Slowing in Clinical Decline

- $\beta$-amyloid (Composite SUVR)
  - Aducanumab
  - $0.19^* \text{(CDR-SB)}$
  - $0.20^* \text{(ADAS-Cog13)}$
  - $0.52^*$

- Tau (CSF p-Tau)
  - $0.20 \text{(CDR-SB)}$
  - $0.11 \text{(ADAS-Cog13)}$
  - $0.19^* \text{(CDR-SB)}$
  - $-0.24^* \text{(MMSE)}$
  - $-0.29^* \text{(ADCS-ADL-MCI)}$

- Clinical outcomes
  - $-0.39^* \text{(MMSE)}$
  - $-0.44^* \text{(ADCS-ADL-MCI)}$

* $p<0.05$ (nominal)

All associations are partial Spearman correlation of change from baseline to Week 78 between each variable.
Results of Study 301 Were Partially Discordant

<table>
<thead>
<tr>
<th>Primary Endpoint</th>
<th>Low-dose aducanumab</th>
<th>High-dose aducanumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDR-SB</td>
<td>-12% (-0.469, 0.110)</td>
<td>-0.18 (-0.262, 0.326)</td>
</tr>
<tr>
<td></td>
<td>p=0.8330</td>
<td>p=0.2250</td>
</tr>
<tr>
<td></td>
<td>2% (-0.35, 0.74)</td>
<td>-6% (-0.62, 0.49)</td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td>-0.1</td>
</tr>
<tr>
<td></td>
<td>(0.326)</td>
<td>(0.49)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary Endpoints</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMSE</td>
<td>-6% (-0.35, 0.74)</td>
<td>-11% (-1.5835, 0.4181)</td>
</tr>
<tr>
<td></td>
<td>0.2</td>
<td>-11% (-1.6067, 0.4309)</td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td>-0.583</td>
</tr>
<tr>
<td></td>
<td>(0.74)</td>
<td>(-1.6067, 0.4309)</td>
</tr>
<tr>
<td></td>
<td>p=0.4795</td>
<td>p=0.2536</td>
</tr>
<tr>
<td>ADAS-Cog-13</td>
<td>-11% (-1.5835, 0.4181)</td>
<td>-11% (-1.6067, 0.4309)</td>
</tr>
<tr>
<td></td>
<td>0.7</td>
<td>0.588</td>
</tr>
<tr>
<td></td>
<td>(-0.35, 0.74)</td>
<td>(-1.6067, 0.4309)</td>
</tr>
<tr>
<td></td>
<td>0.03</td>
<td>(0.326)</td>
</tr>
<tr>
<td></td>
<td>(0.74)</td>
<td>(0.4309)</td>
</tr>
<tr>
<td></td>
<td>p=0.4795</td>
<td>p=0.2536</td>
</tr>
<tr>
<td>ADCS-ADL-MCI</td>
<td>-18% (-0.19, 1.64)</td>
<td>-18% (-0.25, 1.61)</td>
</tr>
<tr>
<td></td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td></td>
<td>(-0.25, 1.61)</td>
<td>(-0.25, 1.61)</td>
</tr>
<tr>
<td></td>
<td>p=0.1225</td>
<td>p=0.1506</td>
</tr>
</tbody>
</table>

n=numbers of randomized and dosed participants included in the analysis
Biomarker Response in High Dose Aducanumab is Lower in Study 301 than in Study 302

- Treatment effect 16.5% smaller
- Cumulative dose 10.4% smaller

- Treatment effect 51.2% smaller
- Cumulative dose 20.3% smaller

**Amyloid PET**

<table>
<thead>
<tr>
<th>Analysis visit, week</th>
<th>Placebo</th>
<th>Low-dose aducanumab</th>
<th>High-dose aducanumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>-0.170</td>
<td>-0.235</td>
</tr>
<tr>
<td>26</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>78</td>
<td>***</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CSF p-Tau**

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Low-dose</th>
<th>High-dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-value</td>
<td>p=0.2726</td>
<td>p=0.3019</td>
<td></td>
</tr>
</tbody>
</table>

**Patients, n**

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Low-dose</th>
<th>High-dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>204</td>
<td>168</td>
<td>124</td>
</tr>
<tr>
<td>Low-dose</td>
<td>198</td>
<td>169</td>
<td>138</td>
</tr>
<tr>
<td>High-dose</td>
<td>183</td>
<td>156</td>
<td>112</td>
</tr>
</tbody>
</table>

*** p<0.001 (nominal)
Study 301 High-Dose Group Diverged From an Otherwise Consistent Association Between Aβ Reduction and Slowing of Clinical Decline

Studies 301, 302, and 103

- Greater extent of amyloid removal
- Amyloid PET composite SUVR adjusted mean difference from placebo
- Favors treatment
- Favors placebo

Bubble size represents sample size at baseline

Greater extent of amyloid removal
Results in Study 301 and 302 Were Partially Discordant

- Supports efficacy of aducanumab
- Low dose clinical
- Low dose β-amyloid PET
- Low dose CSF Tau
- Exposure response relationship
- 302 High dose
- 301 High dose discordant with the set
Summary of Efficacy and Biomarker Results
Studies 301, 302, and 103

<table>
<thead>
<tr>
<th>Diff vs Placebo (%)</th>
<th>Study 301</th>
<th>Study 302</th>
<th>Study 103</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low dose N=547</td>
<td>High dose N=545</td>
<td>Low dose N=543</td>
</tr>
<tr>
<td>CDR-SB</td>
<td>-0.18 (-12%)</td>
<td>0.03 (2%)</td>
<td>-0.26 (-15%)</td>
</tr>
<tr>
<td>MMSE</td>
<td>0.2 (-6%)</td>
<td>-0.1 (3%)</td>
<td>-0.1 (3%)</td>
</tr>
<tr>
<td>ADAS-Cog13</td>
<td>-0.583 (-11%)</td>
<td>-0.588 (-11%)</td>
<td>-0.70 (-14%)</td>
</tr>
<tr>
<td>ADCS-ADL-MCI</td>
<td>0.7 (-18%)</td>
<td>0.7 (-18%)</td>
<td>0.7 (-16%)</td>
</tr>
<tr>
<td>Amyloid-PET*</td>
<td>-0.167 (-38.476)</td>
<td>-0.232 (-53.472)</td>
<td>-0.179 (-41.250)</td>
</tr>
</tbody>
</table>

N=numbers of randomized and dosed participants
(*) Number of participants in 301 PET substudy = 585 and 302 substudy = 488

Dark green = p<0.05 favoring aducanumab
Light green = numeric advantage favoring aducanumab
Differences in Study 301 Are Sufficiently Understood so as Not to Detract From Study 302

- Demographics, disease characteristics, frequency, severity and management of ARIA were all similar between studies
- Underlying pharmacology of aducanumab is similar in Studies 301 and 302
- Differences between studies were largely driven by:
  - Lower exposure to 10 mg/kg dosing in Study 301
  - Imbalance in number and distribution of rapid progressing Alzheimer’s disease patients

In Study 301, patients randomized to groups with the opportunity for full 10mg/kg dosing had results similar to Study 302
Patients Who Had the Opportunity for 14 Doses of 10 mg/kg Had Similar Benefit in Both Studies

Study 301

- Post-PV4, ApoE+ (N=58, n=48)
  - Pre-PV4, ApoE- (N=78, n=66)
  - Post-PV4, ApoE- (N=25, n=23)

Weighted mean (N=161, n=137)

- Favors aducanumab

Study 302

- Post-PV4, ApoE+ (N=65, n=56)
  - Pre-PV4, ApoE- (N=84, n=75)
  - Post-PV4, ApoE- (N=31, n=29)

Weighted mean (N=180, n=160)

N: number at baseline. n: number at Week 78.

Week 78

<table>
<thead>
<tr>
<th></th>
<th>Mean cum dose (mg/kg)</th>
<th>Median cum dose (mg/kg)</th>
<th>% diff vs pbo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-PV4, ApoE-</td>
<td>123.4</td>
<td>150.0</td>
<td>-3%</td>
</tr>
<tr>
<td>Post-PV4, ApoE-</td>
<td>145.9</td>
<td>160.0</td>
<td>-46%</td>
</tr>
<tr>
<td>Weighted mean</td>
<td>122.9</td>
<td>150.0</td>
<td>-29%</td>
</tr>
</tbody>
</table>

Pre-PV4, ApoE- (N=78, n=66)

Post-PV4, ApoE- (N=25, n=23)

Weighted mean (N=161, n=137)

- Favors aducanumab

Weighted mean (N=180, n=160)

- Favors aducanumab

% diff vs pbo

- 29%
- 3%
- 46%
- 25%
- 15%
- 34%
- 23%

Patients who have had the opportunity to complete week 78 visit by 20 March 2019.
Safety
Amyloid-Related Imaging Abnormalities (ARIA)

ARIA refers to radiographic abnormalities observed with anti-Aβ antibodies

- ARIA-Edema (ARIA-E): vasogenic edema or sulcal effusion
- ARIA-Hemorrhage (ARIA-H): brain microhemorrhages or localized superficial siderosis
- May result from increased cerebrovascular permeability as a consequence of antibody binding to deposited amyloid-beta

## Most Common Adverse Events with Aducanumab
### Studies 301 and 302 Placebo-Controlled Period

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>Placebo N=1087</th>
<th>Aducanumab 10 mg/kg N=1033</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients, n (%)</td>
<td></td>
</tr>
<tr>
<td>ARIA-E</td>
<td>29 (2.7)</td>
<td>362 (35.0)</td>
</tr>
<tr>
<td>Headache</td>
<td>165 (15.2)</td>
<td>212 (20.5)</td>
</tr>
<tr>
<td>ARIA-H Brain microhemorrhage</td>
<td>71 (6.5)</td>
<td>197 (19.1)</td>
</tr>
<tr>
<td>Fall</td>
<td>128 (11.8)</td>
<td>155 (15.0)</td>
</tr>
<tr>
<td>ARIA-H Superficial siderosis</td>
<td>24 (2.2)</td>
<td>151 (14.6)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>74 (6.8)</td>
<td>92 (8.9)</td>
</tr>
</tbody>
</table>

- Serious hypersensitivity reactions to aducanumab had an incidence of <0.1%
- Compared to placebo, aducanumab treatment was not associated with abnormalities in vital signs, clinical labs, or ECGs
Clinical and MRI Characteristics of ARIA-E
Studies 301 and 302 Placebo-Controlled Period

- The most common symptoms were headache, confusion, dizziness, and nausea
- Most symptoms were mild (68%) or moderate (28%) in clinical severity
- MRI findings of ARIA-E were typically mild (30%) or moderate (58%) in severity and transient (98% resolved)

<table>
<thead>
<tr>
<th></th>
<th>Placebo N=1076</th>
<th>Aducanumab 10 mg/kg N=1029</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with ARIA-E</td>
<td>29</td>
<td>362</td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>26 (89.7)</td>
<td>268 (74.0)</td>
</tr>
<tr>
<td>Symptomatic</td>
<td>3 (10.3)</td>
<td>94 (26.0)</td>
</tr>
</tbody>
</table>

Each participant counted once, at maximum symptomatic status and severity.
Study 302: Aducanumab Impacts Multiple Clinically Meaningful Dimensions of Alzheimer’s Disease

High dose outcomes at week 78 versus placebo

Primary Endpoint
22% relative reduction in decline from baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)

Secondary Endpoints (Cognition)
MMSE: 18% relative reduction
ADAS Cog: 27% relative reduction

Secondary Endpoint
40% relative reduction in decline in AD Cooperative Study-Activities of Daily Living Inventory Mild Cognitive Impairment Version (ADCS-ADL-MCI)

Exploratory Endpoint
87% relative reduction in decline the Neuropsychiatric Inventory-10 (NPI-10)
Establishing the Safety and Efficacy of Aducanumab

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study 302</strong></td>
<td>A positive study with robust and internally consistent results</td>
</tr>
<tr>
<td><strong>Study 103</strong></td>
<td>An independent, second study providing supportive evidence</td>
</tr>
<tr>
<td><strong>Study 301</strong></td>
<td>A failed study with reasons for difference between studies in results understood and post hoc subgroups supportive of Study 302 and 103</td>
</tr>
</tbody>
</table>

Consistent exposure to 10 mg/kg aducanumab is effective at reducing the clinical decline in patients with early symptomatic Alzheimer’s disease and has a favorable benefit/risk profile.
Conclusion

• Aducanumab targets underlying pathology of disease and is the first investigational drug to show a reduction in clinical decline in patients with Alzheimer’s disease

• Based on prespecified analyses, Study 302 is a robustly positive study, while Study 301 is a failed study

• Differences between Study 301 and 302 were largely driven by:
  ▪ Lower exposure to 10 mg/kg dosing in Study 301
  ▪ Imbalance in number and distribution of rapid progressing Alzheimer’s disease patients

• In Study 301, patients with the opportunity for full 10mg/kg dosing had results similar to Study 302

• A small earlier clinical trial, Study 103, demonstrated a treatment effect on clinical and biomarker endpoints

• Consistent exposure to 10 mg/kg aducanumab is effective at reducing the clinical decline in patients with early symptomatic Alzheimer’s disease and has a favorable benefit/risk profile